Sana Biotechnology SANA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $131.98M-38.8% | $215.67M-17.6% | $261.81M-8.4% | $285.89M+15.0% | ||
| $44.3M-30.8% | $64.04M-12.6% | $73.3M+2.4% | $71.56M+42.0% | ||
| $250.32M-8.2% | $272.72M-7.0% | $293.14M+7.5% | $272.56M-27.4% | ||
| $250.32M-8.2% | $272.72M-7.0% | $293.14M+7.5% | $272.56M-27.4% | ||
| -$250.32M+8.2% | -$272.72M+7.0% | -$293.14M-7.5% | -$272.56M+23.6% | ||
| $3.85M-63.3% | $10.47M+5.4% | $9.94M+164% | $3.76M+457% | ||
| $2.31M+150% | -$4.65M-8,838% | -$52K+92.3% | -$674K-321% | ||
| -$244.17M+8.5% | -$266.76M+5.8% | -$283.26M-5.1% | -$269.48M+24.3% | ||
| -$0.97+16.4% | -$1.16+21.1% | -$1.47-2.8% | -$1.43+42.8% | ||
| -$0.97+16.4% | -$1.16+21.1% | -$1.47-2.8% | -$1.43+33.2% | ||
| 989.7M+7.8% | 918M+17.9% | 778.8M+3.7% | 751.2M+14.2% | ||
| 989.7M+7.8% | 918M+18.4% | 775.3M+3.2% | 751.2M— | ||
| $3.85M-63.3% | $10.47M+5.4% | $9.94M+164% | $3.76M+457% | ||
| $2.31M+150% | -$4.65M-8,838% | -$52K+92.3% | -$674K-321% | ||
| $29.43M+431% | -$8.88M— | —— | -$84.88M— | ||
| -$250.32M+8.2% | -$272.72M+7.0% | -$293.14M-7.5% | -$272.56M+23.6% | ||
| —— | —— | —— | -$256.96M+25.7% | ||
| -$250.32M+8.2% | -$272.72M+7.0% | -$293.14M-7.5% | -$272.56M+23.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Sana Biotechnology profitable?
- Sana Biotechnology is not currently profitable: it reported a net loss of $242.0M over the trailing twelve months.
- What is Sana Biotechnology's earnings per share?
- Sana Biotechnology's diluted EPS over the trailing twelve months is $-0.93.
- Where does Sana Biotechnology's income statement data come from?
- Every line is extracted from Sana Biotechnology's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.